The development of blood cells requires the interplay of hematopoietic stem and progenitor cells, marrow stroma and polypeptide growth factors. Although many proteins support the expansion of megakaryocytic precursor cells, identification of the late acting, lineage specific growth factor for platelet production, termed Thrombopoietin (Tpo), has remained elusive. Recently, characterization of the proto-oncogene c-mpl revealed structural homology with the hematopoietic cytokine receptor family. Based on the cell of origin of its cDNA, we hypothesized that the ligand for c- mpl might be identical with Tpo, and in collaboration with scientists at ZymoGenetics recently cloned its cDNA. Using recombinant protein we have shown that the mpl-ligand displays all of the expected biological properties of the major regulator of megakaryocyte development, and proposed that it be termed Thrombopoietin (Tpo). In the present proposal we hope to expand upon these results and study its cellular and molecular biology. Specifically, we propose a research plan of three specific aims. In the first, we will determine whether Tpo gene expression is regulated, localize the cellular site(s) of its production, identify the proximate signal for Tpo release and establish an in vitro model to study the molecular mechanisms underlying its expression. Although Tpo was initially cloned based on its ability to stimulate cells expressing c-mpl, multiple lines of evidence suggest that alone, this cell surface protein may not constitute the high affinity signalling Tpo receptor. To precisely define the molecular composition of the complete Tpo receptor, our second specific aim is designed to determine the binding affinity of ligand for the various component parts, reconstitute a cell surface complex which transmits a Tpo signal in naive cells, and identify the critical secondary messengers responsible for Tpo-induced proliferation and differentiation of target cells. We strongly suspect that this involves potentially novel transcription factors and propose to clone cDNA for the proteins involved in Tpo-induced signalling. And in the third specific aim, we will study the effects of Tpo on megakaryocytes and their purified progenitors, on both the cellular and molecular levels. We anticipate that successful completion of the proposed research will provide insights into the biology of platelet production and in a more general way, contribute to our understanding of the regulation of cell proliferation and differentiation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK049855-04
Application #
2713413
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Badman, David G
Project Start
1995-06-01
Project End
1999-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Zhan, H; Lin, C H S; Segal, Y et al. (2018) The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms. Leukemia 32:462-469
Zhan, H; Ma, Y; Lin, C H S et al. (2016) JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation. Leukemia 30:2332-2341
Lin, Chi Hua Sarah; Kaushansky, Kenneth; Zhan, Huichun (2016) JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms. Blood Cells Mol Dis 62:42-48
Kaushansky, Kenneth (2015) Thrombopoiesis. Semin Hematol 52:4-11
Sangkhae, Veena; Etheridge, S Leah; Kaushansky, Kenneth et al. (2014) The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood 124:3956-63
Etheridge, S Leah; Roh, Michelle E; Cosgrove, Megan E et al. (2014) JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. Proc Natl Acad Sci U S A 111:2295-300
Jung, Andre Scott; Kaushansky, Alexis; Macbeath, Gavin et al. (2011) Tensin2 is a novel mediator in thrombopoietin (TPO)-induced cellular proliferation by promoting Akt signaling. Cell Cycle 10:1838-44
Saur, Sebastian J; Sangkhae, Veena; Geddis, Amy E et al. (2010) Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 115:1254-63
Fox, Norma E; Lim, Jihyang; Chen, Rose et al. (2010) F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents. Exp Hematol 38:384-91
Geddis, Amy E (2010) Megakaryopoiesis. Semin Hematol 47:212-9

Showing the most recent 10 out of 64 publications